How to Get Prescription Weight Loss Pills UK

How to get prescription weight loss pills in the UK involves understanding eligibility criteria, available medicines and the right pathway for your circumstances. Several MHRA-authorised treatments are available, including orlistat, GLP-1 receptor agonists such as semaglutide (Wegovy) and liraglutide (Saxenda), the dual agonist tirzepatide (Mounjaro), and newer options including oral semaglutide and orforglipron (Foundayo). Access may be through your NHS GP, a specialist weight management service, or a regulated private provider. This guide explains who qualifies, what medicines exist, how to obtain a prescription safely, what side effects to expect, and what treatment is likely to cost.

Who can get prescription weight loss medication on the NHS?

NHS weight loss medication requires a minimum BMI, at least one weight-related condition such as type 2 diabetes, and evidence that lifestyle interventions have been tried; local ICB commissioning decisions mean availability varies across the UK.

NHS prescription weight loss medication is available to adults who meet specific clinical criteria, which differ by medicine and are set out in individual NICE technology appraisals rather than a single universal threshold. Eligibility criteria, service settings and any time-limited use conditions vary between products, so it is important not to assume that meeting a BMI threshold alone is sufficient.

As a general guide, NICE technology appraisals for weight-management medicines typically require a minimum BMI (which may be lower for people from certain ethnic backgrounds who are at higher metabolic risk), the presence of at least one weight-related health condition such as type 2 diabetes or hypertension, and evidence that lifestyle interventions have not produced sufficient results.^[1][2] Some medicines are recommended only within specialist weight-management services and for a defined treatment period. Your GP or specialist will assess your overall health, existing conditions and whether you have engaged with a structured weight management programme before recommending a medicine.

Commissioning decisions in England are made by local Integrated Care Boards (ICBs). In Scotland, Wales and Northern Ireland, equivalent decisions are made by regional health boards and commissioners under their respective devolved health systems. Even where NICE recommends a medicine, local commissioners may have their own criteria or phased rollout plans, so NHS availability can vary across the UK. Speaking to your GP is the most reliable first step to understanding what is currently accessible in your area.

Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, and is one option for people exploring both NHS and private pathways.

What are the main prescription weight loss pills available in the UK?

MHRA-authorised options include orlistat, semaglutide injection (Wegovy), oral semaglutide (Wegovy 25 mg tablets), liraglutide (Saxenda), tirzepatide (Mounjaro) and orforglipron (Foundayo), each with a distinct mechanism, dosing schedule and eligibility criteria.

Several prescription medicines are currently authorised in the UK for chronic weight management, and they work through distinct mechanisms. The main options include orlistat, semaglutide (Wegovy injection), liraglutide (Saxenda), tirzepatide (Mounjaro), oral semaglutide for weight management (Wegovy 25 mg tablets), and orforglipron (Foundayo).

Orlistat is a lipase inhibitor taken with meals that reduces the absorption of dietary fat by approximately one third. It is available on the NHS and, at a lower dose, as a pharmacy medicine without a prescription.^[4]

Semaglutide injection (Wegovy) is a glucagon-like peptide-1 (GLP-1) receptor agonist given as a weekly subcutaneous injection. It works by mimicking a gut hormone that regulates appetite and slows gastric emptying. The injectable form is available in doses up to 2.4 mg weekly, with a higher 7.2 mg strength also authorised by the MHRA.

Oral semaglutide for weight management (Wegovy 25 mg tablets) received MHRA authorisation on 11 June 2026.^[7] It is a distinct product from Rybelsus with its own licensed posology and is not interchangeable with the injectable form.

Liraglutide (Saxenda) is also a GLP-1 receptor agonist, administered as a daily subcutaneous injection.

Tirzepatide (Mounjaro) is a dual GIP and GLP-1 receptor agonist given as a weekly subcutaneous injection using a multiple-dose KwikPen.^[10][11] It is MHRA-authorised in the UK both for type 2 diabetes and for chronic weight management in adults.^[12][13]

Orforglipron (Foundayo) is an oral GLP-1 receptor agonist licensed in the UK for weight management in adults.

Each medicine has a different dosing schedule, side-effect profile and eligibility criteria. A prescriber will consider your medical history, any contraindications and your individual treatment goals before recommending one over another.

How do you get a prescription, through your GP or a private clinic?

Your NHS GP is the best starting point; if NHS access is limited, a private prescription can be issued by a registered prescriber following a full clinical consultation through a CQC-registered provider in England.

You can obtain a prescription for weight loss medication through your NHS GP, a specialist weight management service, or a regulated private provider, and the right route depends on your circumstances and local NHS availability. Your GP is usually the best starting point: they can assess your eligibility, review your medical history and refer you to a specialist service if needed. In some areas, NHS specialist weight management clinics can prescribe medicines such as Wegovy or Mounjaro as part of a structured programme.

If NHS access is limited in your area, or if you prefer not to wait, a private route is an option. Private prescriptions can be issued by a registered doctor or independent prescriber following a clinical consultation. It is important to choose a provider regulated by the appropriate body. In England, online clinics should be registered with the Care Quality Commission (CQC). In Scotland, relevant services are overseen by Healthcare Improvement Scotland (HIS); in Wales, by Healthcare Inspectorate Wales (HIW); and in Northern Ireland, by the Regulation and Quality Improvement Authority (RQIA).

Any pharmacy dispensing your prescription should be registered with the appropriate pharmacy regulator. The General Pharmaceutical Council (GPhC) registers and inspects pharmacy premises in Great Britain; you can verify a pharmacy's registration at pharmacyregulation.org. In Northern Ireland, pharmacies are regulated by the Pharmaceutical Society of Northern Ireland (PSNI). You can verify a prescriber's registration at gmc-uk.org.

When using an online service, a thorough consultation should include a review of your medical history, current medicines, BMI, and any contraindications. A prescriber should not issue a prescription without this assessment. Mounjaro is one option a prescriber may consider after an online consultation with Bolt Pharmacy, a GPhC-registered UK online pharmacy, and is only prescribed where it is clinically appropriate.

Whichever route you choose, ongoing monitoring and support are an important part of safe and effective treatment.

What side effects should you know about before starting treatment?

GLP-1 receptor agonists and tirzepatide commonly cause nausea, vomiting and diarrhoea, particularly during dose escalation; acute pancreatitis has been reported and requires prompt medical attention if severe abdominal pain develops.

Prescription weight loss medicines can cause side effects, and understanding these before starting treatment helps you make an informed decision and recognise when to seek advice. The side effects vary by medicine class.

Orlistat commonly causes gastrointestinal effects including oily or fatty stools, increased bowel frequency and flatulence, particularly if dietary fat intake remains high. These effects are dose-dependent and often improve with a lower-fat diet.

GLP-1 receptor agonists (semaglutide injection, oral semaglutide, liraglutide, orforglipron) and the dual agonist tirzepatide share a broadly similar gastrointestinal side-effect profile:

• Nausea, vomiting and diarrhoea are the most commonly reported effects, particularly during dose escalation

• Constipation and abdominal discomfort are also reported

• Reduced appetite is an intended effect but can occasionally lead to inadequate nutrition if not managed

• Severe or prolonged vomiting and diarrhoea can cause dehydration; ensure adequate fluid intake and seek medical advice if symptoms are severe

Acute pancreatitis has been reported with GLP-1 receptor agonists and tirzepatide, including post-marketing reports of necrotising pancreatitis and reports with a fatal outcome.^[15][16] If you develop persistent, severe abdominal pain, contact your GP promptly or call NHS 111 for urgent advice. If you experience a life-threatening emergency, call 999 or go to A&E.

Gallbladder disease, including gallstones, has been reported with GLP-1 receptor agonists and tirzepatide.^[17][18] Seek medical advice promptly if you develop pain in the upper right abdomen, fever or yellowing of the skin or eyes.

When GLP-1 receptor agonists or tirzepatide are used alongside insulin or sulfonylureas, there is an increased risk of hypoglycaemia (low blood sugar).^[10][11] Your prescriber should review your doses of these medicines and advise on monitoring.

For people with pre-existing pre-proliferative or proliferative diabetic eye disease, rapid improvement in blood glucose control may be associated with transient worsening of diabetic retinopathy.^[10][11] Your prescriber should be aware of your eye health history.

Pregnancy, breastfeeding and contraception: GLP-1 receptor agonists, tirzepatide and orforglipron are not recommended during pregnancy or breastfeeding. If you are pregnant, planning a pregnancy or breastfeeding, discuss this with your prescriber before starting treatment. Effective contraception is recommended for women of childbearing potential during treatment. If you become pregnant while taking one of these medicines, stop treatment and contact your prescriber promptly.

If you experience a suspected side effect, you or your healthcare professional can report it to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Reporting helps the MHRA monitor the safety of medicines in real-world use.

How much do prescription weight loss treatments cost in the UK?

NHS patients in England pay the standard prescription charge per item, while private costs vary by medicine and provider; orlistat is generally the most affordable option, with injectable treatments carrying higher private costs.

The cost of prescription weight loss treatment in the UK depends on whether you access it through the NHS or privately, and which medicine is prescribed. NHS patients in England pay the standard prescription charge per item; current charges and prepayment certificate (PPC) fees are published by the NHS Business Services Authority (NHSBSA) at nhsbsa.nhs.uk, and it is worth checking there for the most up-to-date figures. A PPC can represent a significant saving for people who require multiple items regularly. Prescription charges do not apply in Wales, Scotland or Northern Ireland.

For those accessing treatment privately, costs vary considerably depending on the medicine, dose strength and the provider. Private prices are set by individual clinics and pharmacies and are not regulated in the same way as NHS charges. Any list prices published in sources such as the BNF reflect the drug tariff or manufacturer list price and are not the same as private retail prices, which may differ. Always confirm the full cost of a consultation and any prescription separately, as these are distinct charges.

It is also worth noting that the UK Mounjaro presentation is a multiple-dose KwikPen containing four weekly doses per pen, which is relevant when comparing costs across providers.^[20][21]

Orlistat is generally the most affordable option and is available at lower cost as a pharmacy medicine. Injectable GLP-1 and dual agonist treatments tend to carry higher private costs, reflecting their more complex manufacture and delivery systems.

When comparing providers, look beyond price alone. Regulatory registration, the quality of the clinical consultation, ongoing monitoring and access to prescriber support are all important factors. A low headline price that does not include adequate clinical oversight may not represent good value or safe care. If cost is a barrier, speaking to your GP about NHS eligibility remains the most appropriate first step. Information on help with health costs is available from the NHSBSA at nhsbsa.nhs.uk.

Scientific References

1. Overweight and obesity management – a guide for prescribing medicines to manage overweight and obesity (NG246).
2. Overweight and obesity in adults.
3. Mode of action of orlistat. Guerciolini R. International Journal of Obesity and Related Metabolic Disorders..
4. Orlistat: a medicine to treat obesity.
5. Single-dose 7.2 mg semaglutide (Wegovy) pen approved to treat adult patients with obesity.
6. Medicines regulator approves up to 7.2 mg dose of semaglutide (Wegovy) for patients with obesity only.
7. First GLP-1 tablet for weight loss approved in the UK.
8. Wegovy | European Medicines Agency (EMA).
9. Rybelsus (semaglutide tablets) – transition to new formulation and risk of medication error.
10. Mounjaro KwikPen 10 mg solution for injection in pre-filled pen (tirzepatide) – Summary of Product Characteristics.
11. Mounjaro, INN-tirzepatide – EPAR product information.
12. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
13. Tirzepatide: a medicine to manage type 2 diabetes and obesity.
14. UK first in Europe to authorise orforglipron for weight management and type 2 diabetes.
15. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists – strengthened warnings on acute pancreatitis including necrotising and fatal cases.
16. Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database. Frontiers in Pharmacology..
17. Incretin-based drugs and the risk of gallbladder or biliary tract diseases among patients with type 2 diabetes across categories of body mass index: a nationwide cohort study. The Lancet Regional Health – Western Pacific..
18. Association of incretin-based therapies with hepatobiliary disorders among patients with type 2 diabetes: a case series from the FDA adverse event reporting system. Endocrine Connections..
19. GLP-1 medicines for weight loss and diabetes: what you need to know.
20. Mounjaro 2.5 mg KwikPen – patient information leaflet.
21. Four-dose Mounjaro KwikPen approved by MHRA for diabetes and weight management.

Frequently Asked Questions